Resistance to Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)

Resistance refers to the gradual loss of sensitivity or effectiveness of a drug during treatment. ForPhesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf), there are several potential drug resistance mechanisms, such asvariations in the HER2 signaling pathway, downregulation of cell surface receptors, immune evasion, etc.. Understanding the drug resistance mechanism of Phesgo and adopting corresponding treatment strategies will help improve the therapeutic effect of Phesgo and reduce the emergence of drug resistance.

Phesgo mainly inhibits the growth and spread of tumors by targeting the HER2 signaling pathway. If tumor cells develop HER2 gene mutations or mutations in other related signaling pathway molecules, it may lead to resistance to Phesgo. One of the ingredients in Phesgo is Trastuzumab, which inhibits the growth of tumor cells by binding to the HER2 receptor. However, certain tumor cells may downregulate or lose expression of the HER2 receptor, thereby reducing Phesgo's efficacy. Another ingredient of Phesgo is Hyaluronidase, which helps improve drug permeability and immune cell infiltration. However, tumor cells can evade immune attack by changing the expression of their immune-related molecules or activating inhibitory immune evasion mechanisms, leading to Phesgo resistance.

The original Phesgo drug is not marketed in the country and therefore cannot be included in medical insurance. Since Phesgo's original drug has been on the market overseas for a short time, there is less price and other related information. For specific prices and drug information, please consult Yaode's medical consultant.